Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Recent data suggest that radioimmunotherapy with 131I-tositumomab or 90Y-ibritumomab tiuxetan not only induces high response rates but also results in durable remissions in patients with relapsed or refractory indolent non-Hodgkin's lymphomas. Even more notable response rates have been observed when radioimmunotherapy is used as front-line treatment in patients with indolent non-Hodgkin's lymphomas. The use of radioimmunotherapy has been evaluated in the treatment of aggressive lymphomas with promising results, but it remains investigational. Standard doses of radioimmunotherapy given as a conditioning regimen for hematopoietic stem-cell transplant or myeloablative doses of radioimmunotherapy given in conjunction with stem-cell support have yielded encouraging outcomes with durable remissions and a low incidence of treatment-related mortality. SUMMARY:
|
Authors | Steven I Park, Oliver W Press |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 14
Issue 6
Pg. 632-8
(Nov 2007)
ISSN: 1065-6251 [Print] United States |
PMID | 17898567
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Radiopharmaceuticals
- ibritumomab tiuxetan
- tositumomab I-131
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Lymphoma
(immunology, therapy)
- Lymphoma, B-Cell
(immunology, therapy)
- Radioimmunotherapy
(methods)
- Radiopharmaceuticals
(therapeutic use)
|